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Abstract: Defining optimal antibiotic dosing for treatment of lung
infections is challenging because of the interrelationship between
patient characteristics (eg, pathophysiological changes of lung during
an infection, albumin level, renal function), antibiotic characteristics
(eg, physicochemical properties, protein binding), and bacterial
pathogen susceptibility. Measurement of antibiotic concentration in the
lung compartments, such as epithelial lining fluid (ELF), is important
to describe the drug exposure at site of infection. This article reviews
published data on antibiotic penetration described by the ELF to
plasma (ELF:plasma) ratios and the probability of pharmacokinetic/
pharmacodynamics (PK/PD) attainment at the target site with current
dosing regimens to outline dosing strategies that could optimize the
PK/PD indices. Antibiotic physicochemical properties could be used to
predict the extent of penetration into the lung tissues. Lipophilic
antibiotics penetrate well into the lung compartments; however,
standard dosing regimens generally seem to be insufficient to achieve
optimal PK/PD indices in the ELF, particularly during severe infec-
tions. Aggressive dosing regimens are required for antibiotics that
poorly or moderately penetrate the lung tissues, whereas nebulization
could be the alternative method to enhance antibiotic concentration at
the target site. Special populations such as the critically ill, patients on
renal replacement therapy, and those with renal impairment need
dosing to be individualized, as these populations have high PK vari-
ability. Dosing based on free drug concentrations should be considered
preferred, as these concentrations frequently reflect the antibiotic
concentration at the target site. Therefore, the use of therapeutic drug
monitoring should be considered necessary, whenever possible, to
guide dosing in lung infection.
Key Words: pharmacodynamics, pharmacokinetics, PK/PD, pulmo-
nary, therapeutic drug monitoring
(Clin Pulm Med 2013;20:121–128)
Lung infection is common in hospitalized patients and isassociated with considerable morbidity and mortality. This
was comprehensively shown in a prevalence study of infection
in the intensive care unit (ICU), where 64% of infections were
respiratory infections in which these patients had higher ICU
and hospital mortality rates.1 Inadequate empirical antibiotic
therapy is associated with reduced survival in patients with
severe lung infection2 and, thus early and appropriate
antibiotic therapy is an essential intervention.3 Optimizing
antibiotic exposure for lung infections is challenging, espe-
cially when considering drug penetration into the lung tissue.
Although infection can occur throughout most of the lung,
alveolar compartments such as epithelial lining fluid (ELF) or
the cells (alveolar macrophage, AM) are considered as the area
where pathogens commonly accumulate during lung infections
and thus antibiotic penetration into such compartments is of
high importance.4 Sufficient antibiotic concentrations in the
ELF or AM are likely to enable optimal antibiotic activity at
the site of infection in the lung. However, changes in the lung
pathology in infected patients may reduce the likelihood of
achieving target concentrations at the site of infection.
The decreasing susceptibility of respiratory pathogens
further complicates this situation. On the basis of the European
Committee on Antimicrobial Testing (EUCAST),5 the mini-
mum inhibitory concentration (MIC) breakpoint for the clas-
sical respiratory pathogen, Streptococcus pneumoniae reached
2mg/L for the commonly used antibiotic, levofloxacin.
Although in cases of nosocomial infection, MIC breakpoints
for gram-negative pathogens, for example, Pseudomonas
aeruginosa (16mg/L for piperacillin/tazobactam), can be high
and difficult to achieve in some patients.
The objective of this paper is to review and interpret the
data describing antibiotic pharmacokinetics/pharmacody-
namics (PK/PD) in critically ill patients with lung infections
and to discuss target site penetration and the potential need for
altered dosing strategies to increase the likelihood of suc-
cessful treatment.
SEARCH STRATEGY AND SELECTION CRITERIA
A PubMed search using relevant keywords was undertaken
to identify relevant recently published the English language arti-
cles. Journal articles referenced in the primary article identified,
if appropriate, were also cited. Search terms included:
“carbapenem,” “cephalosporin,” “penicillin,” “fluoroquinolone,”
“aminoglycoside,” “oxazolidinone,” “macrolide,” “ketolide,”
“colistin,” “lung infection,” “respiratory infection,” “pneumonia,”
“epithelial lining fluid,” “alveolar concentration,” “intrapulmonary
concentration,” “pharmacokinetic,” and “pharmacodynamic.” To
emphasize the antibiotic PK/PD data in the lung tissue, only
articles with data on antibiotic concentrations in blood and ELF
were included.
PK/PD INDICES RELATED TO ANTIBIOTIC
EFFICACY AND RESISTANCE
Achieving PK/PD indices associated with maximal bac-
terial killing will increase the likelihood of treatment efficacy.
PK/PD relates PK parameters to PD, which describe antibiotic
activity at different concentrations.6 Different PK/PD indices
have been defined for different classes of antibiotics (Table 1).
These relationships have been defined through in vitro and
in vivo studies in animals and humans.7–9 For optimal bac-
tericidal activity in the lung, high penetration into the ELF,
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which is defined by the ELF concentrations relative to plasma,
is likely to be advantageous.
PATHOPHYSIOLOGY CHANGES IN LUNG
INFECTIONS AND FACTORS INFLUENCING
ANTIBIOTIC PENETRATION INTO ELF
Many factors could contribute to the pathogenesis of lung
infections such as nasal colonization, oropharyngeal or gastric
colonization, aspiration or colonization of the artificial airway.
The invasion of pathogens into the lung parenchyma stimulates
immune mechanisms of defense. As the process progresses,
pathogens can reach the alveoli with host defenses quickly
overwhelmed by the virulence of the microorganism and/or the
inoculum size. The ELF is the fluid that fills the alveolar space.
To reach the ELF, the antibiotic must be able to diffuse across
the blood-alveolar barrier, in which it depends on its phys-
icochemical characteristics (eg, lipophilicity, molecular
weight, protein binding) and patient-specific characteristics
(eg, tissue permeability, renal function).
Physicochemical Properties
Excellent penetration into the alveolar compartments is
more common with lipophilic antibiotics (eg, fluo-
roquinolones, macrolides, oxazolidinones).10 The ELF to
plasma ratio (ratio of the area under the concentration time
curve (AUC) of antibiotic for 1 dosing interval in ELF:plasma)
of fluoroquinolones is reported to be >100% when adminis-
tered by either the oral or intravenous (IV) route.11–13
Numerous studies have reported the extensive penetration of
fluoroquinolones into the lung tissue (eg, AM)13,14 with con-
centrations that were higher than those in plasma and ELF.
Similarly with tigecycline and oxazolidinones, the ELF to
plasma penetration is also high.15,16 Inversely for hydrophilic
antibiotics (eg, aminoglycosides, glycopeptides), poorer pen-
etration into the lung compartments has been reported in many
studies. The aminoglycosides’ ELF:plasma penetration ratio
has been reported between 12% and 32% in critically ill
patients with severe lung infection.17,18 The ELF:plasma
penetration ratio for vancomycin is reported to be approx-
imately B15% in a similar population.19 These data support
the importance of drug physicochemistry as 1 important
determinant of drug penetration.
Protein Binding
The importance of the free, or unbound, drug exposure at
the site of lung infection (ELF) has been advocated by many
studies.12,20–22 Measurement of unbound concentrations in the
ELF is likely to best describe antibiotic activity, particularly
for highly protein bound antibiotics. In a prospective PK study
of 13 critically ill patients with ventilator-associated pneu-
monia (VAP) treated with teicoplanin (> 85% protein binding),
the median unbound teicoplanin concentrations in blood and
ELF were similar,21 which suggested that the unbound fraction
of drug penetrated well into the lung tissue. Dose adjustment
should be made in patients with low albumin concentrations,
such as critically ill patients, and the unbound fraction in blood
could guide dosing.
Tissue Permeability
Another important factor that might influence the pene-
tration of antibiotic into the alveolar compartments is tissue
permeability, although predicting permeability may be diffi-
cult. Lamer et al19 reported that in critically ill patients treated
with IV vancomycin, that significantly higher vancomycin
penetration was seen in patients with higher albumin concen-
trations in the ELF, 25% versus 14% (P < 0.02). In this context,
albumin movement from plasma into ELF was seen as an
indicator of lung inflammation and that inflammation was
associated with higher antibiotic concentrations in ELF.
RECENT PK STUDIES OF VARIOUS ANTIBIOTICS:
ELF PENETRATION WITH PK/PD TARGET
ATTAINMENT
Recent PK studies have showed variable antibiotic pen-
etration into the lung tissue based on ELF:plasma ratios. Of
interest is the question whether current antibiotic dosing reg-
imens optimize PK/PD target attainment at the site of lung
infection. Studies comparing the ELF concentrations and
plasma concentrations have generally shown that lipophilic
antibiotics have superior penetration into the lung
tissue. Table 2 summarizes the recently published PK studies
and data on ELF:plasma ratios and the probability of PK/PD
target attainment in the ELF for different current dosing reg-
imens of different antibiotic classes.
b-lactam
b-lactam penetration into the lung tissue is variable.
Penicillins penetrate the lung tissue approximately 40% to
50%,23,24 cephalosporins range from 30% to 100%,26,37,38 and
carbapenems about 30% to 40%.27,28,39 Standard doses that
achieve PK/PD targets in blood are unlikely to achieve the
same targets in the presence of severe nosocomial
TABLE 1. The PK/PD Indices of Different Class of Antibiotics
Antibiotic-Killing
Characteristics Definition of PK/PD Indices PK/PD Indices
Concentration
dependent
Ratio of the peak antibiotic concentration (Cmax)
to the MIC of the pathogen (Cmax/MIC)
Cmax/MIC= 8-10
(aminoglycoside)
Time dependent Percentage of time during dosing interval for
which the free concentration remain above the
MIC of the pathogen (%f T>MIC)
40%-70% f T>MIC
(b-lactams)
40%-80% f T>MIC (linezolid)
Concentration
dependent with
time dependent
Ratio of the area under the concentration-time
curve during a 24 h period (AUC0-24) to the
MIC of the pathogen (AUC0-24/MIC)
AUC0-24/MIC> 125
(fluoroquinolone)
AUC0-24/MICZ400
(vancomycin)
AUC0-24/MIC> 50 (colistin)
%f T>MIC indicates percentage of time in which the free drug concentration is above the MIC of the pathogen; AUC0-24,
area under the concentration-time curve during a 24-hour period; Cmax, maximum concentration; MIC, minimum inhibitory
concentration; PK/PD, pharmacokinetic/pharmacodynamics.
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TABLE 2. Plasma and ELF Concentrations of Different Class of Antibiotics (Oral and IV)
Antibiotics
Dosage
Regimen
Population [No.
Patients (n)]
Sampling
Time (h)w
Plasma
Concentration
(mg/L)z
ELF
Concentration
(mg/L)z
ELF:Plasma
Ratioz
Probability PD
Target
Attainment in
ELF*
b-lactams
Piperacillin
(Boselli
et al23)
4.5 g 8 h Critically ill patients,
severe bacterial
pneumonia (n = 10)
Steady
state
24.0 ± 13.8 13.6 ± 9.40 0.578 Low
Piperacillin
(Boselli
et al24)
4.5 g (LD),
13.5 g/d (CI)
Critically ill patients
with VAP (n = 20)
Steady
state
25.3 (23.1-
32.6)y#
102.4 (97.4-
112.6)y**
12.7 (6.7-18.0)y#
44.1 (33.4-48.3)y**
0.46 Medium
(MIC< 8mg/L)
Piperacillin
(Boselli
et al24)
4.5 g (LD),
18 g/d (CI)
Critically ill patients
with VAP (n = 20)
Steady
state
38.9 (32.9-
59.6)y#
135.3 (119.5-
146.2)y**
19.1 (14.0-
21.5)y#
54.9 (45.2-
110.3)y**
0.43 Medium
(MIC< 16mg/L)
Ceftazidime
(Boselli
et al25)
2 g (LD),
4 g/d (CI)
Critically ill patients
(n = 15)
Steady
state
39.6 ± 15.2 8.2 ± 4.8 0.218 Low
(MIC> 2mg/L)
Cefepime
(Boselli
et al26)
2 g (LD),
4 g/d (CI)
Critically ill patients
with severe
nosocomial
pneumonia (n = 20)
Steady
state
13.5 ± 3.3 13.7 ± 3.0 1.048 Low
(MIC> 4mg/L)
Meropenem
(Conte
et al27)
0.5 g 8 h4 doses Healthy volunteers
(n = 20)
1
2
3
5
8
10.9 ± 1.3
5.2 ± 1.6
2.4 ± 0.9
0.3 ± 0.4
0.0 ± 0.0
5.3 ± 2.5
2.7 ± 1.8
1.9 ± 0.9
0.7 ± 0.4
0.2 ± 0.1
0.49-0.80 Low
Meropenem
(Conte
et al27)
1 g 8 h4 doses Healthy volunteers
(n = 20)
1
2
3
5
8
19.0 ± 7.6
7.5 ± 1.3
5.3 ± 1.5
2.0 ± 1.3
0.0 ± 0.0
7.7 ± 3.1
4.0 ± 1.1
1.7 ± 1.4
0.8 ± 0.4
0.0 ± 0.0
0.32-0.53 Low
Meropenem
(Conte
et al27)
2 g 8 h4 doses Healthy volunteers
(n = 8)
1
3
60.9 ± 8.0
12.8 ± 2.7
2.9 ± 1.0
2.8 ± 1.5
0.18
0.28
Low
Ertapenem
(Boselli
et al28)
1 g 24 h Critically ill patients
with early-onset VAP
(n = 15)
1
12
24
30.3 (27.1-37.8)y
4.8 (3.9-6.4)y
0.8 (0.5-1.2)y
9.4 (8.0-10.7)y
2.0 (1.1-2.5)y
0.3 (0.2-0.4)y
0.32 (0.28-
0.46)y
Medium
(MICr4mg/L)
Macrolides
Azithromycin
(Capitano
et al13)
500mg first dose
then 250mg
daily4 doses
(oral)
Patients undergoing
diagnostic
bronchoscopy (n = 16)
4
8
12
24
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.9
0.0 ± 0.0
0.6 ± 0.4
0.7 ± 0.4
0.9 ± 0.5
0.9 ± 0.7
6.4
13.2
12.6
31.3
Medium
(MIC< 1mg/L)
Azithromycin
(Rodvold
et al29)
500mg daily5
doses (IV)
Healthy volunteers
(n = 12)
4
12
24
0.4 ± 0.1
0.3 ± 0.0
0.1 ± 0.0
1.7 ± 0.7
1.3 ± 0.5
2.9 ± 1.8
4.6
5.1
20.4
High
Fluoroquinolones
Levofloxacin
(Nicolau
et al14)
750mg daily5 d
(oral)
Acute exacerbation of
chronic bronchitis
(n = 18)
4
12
24
8.0 ± 2.5
5.8 ± 1.2
2.2 ± 1.2
7.5 ± 3.1
8.4 ± 6.0
1.2 ± 0.9
0.98
0.58
Medium
(MICr1mg/L)
Levofloxacin
(Zhang
et al30)
500mg single
dose (oral)
Patients with lower
respiratory tract
infections (n = 40)
1.2 ± 0.1
4.1 ± 0.2
8.1 ± 0.1
12.1 ± 0.1
24.2 ± 0.1
3.3 ± 3.0
4.1 ± 1.9
2.1 ± 1.1
1.9 ± 0.6
0.9 ± 0.6
3.4 ± 3.7
2.4 ± 2.0
1.6 ± 1.5
1.0 ± 0.9
0.9 ± 0.7
0.8 ± 0.4
0.6 ± 0.5
0.7 ± 0.3
0.5 ± 0.6
1.0 ± 0.9
Low
Levofloxacin
(Boselli
et al31)
500mg daily2 d
(IV)
Critically ill patients,
severe CAP (n = 12)
1
24
12.6 (12.0-14.1)y
3.0 (2.1-3.3)y
11.9 (8.7-13.7)y
3.9 (2.1-5.7)y
1.3 ± 3.1
1.2 ± 3.6
Medium
(MICr1mg/L)
Levofloxacin
(Boselli
et al31)
500mg 12 h2 d
(IV)
Critically ill patients,
severe CAP (n = 12)
1
12
19.7 (19.0-22.0)y
7.7 (7.4-11.9)y
17.8 (16.2-23.5)y
11.8 (10.3-16.7)y
1.3 ± 4.6
1.1 ± 4.0
High
(MIC> 1mg/L)
Glycopeptides
Vancomycin
(Lamer
et al19)
15mg/kg (at least
5 d) (IV)
Critically ill,
ventilated (n = 14)
24 24.0 ± 10.0 4.5 ± 2.3 0.28 Low
Vancomycin
(Georges
et al32)
30mg/kg daily
(IV)
Critically ill,
ventilated, MRSA
pneumonia (n = 10)
24 16.3 ± 5.8 0.8 ± 1.18 0.08 Low
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infection.23–26 It follows that more aggressive dosing regimens
may be required, especially in severe infections with more
resistant pathogens. Continuous infusion (CI) could also be
used as alternative administration for b-lactams in lung
infections.24–26,40,41 In patients with moderate to severe renal
failure, a reduction in drug clearance may help in the ach-
ievement of PK/PD targets with usual dosing regimens.24
Macrolides
The macrolides penetrate well into the lung tissue
(> 100% ELF:plasma ratio).13,29,42 Previous studies have
consistently reported significantly higher concentrations in
ELF and AM than in plasma throughout the therapy course,
with concentrations in AM always far higher than ELF. Rapid
distribution of macrolides into the lung compartments had
resulted in lower plasma concentrations throughout dosing
interval,13,29,42 thus leading to theoretical concerns of its use in
primary bacteremia. In healthy adults administered standard
doses of azithromycin, at the end of 24-hour dosing interval,
100% ELF concentrations (n = 4) were above the susceptibility
breakpoint of 1mg/L.29 Although standard doses achieve
desired concentrations in the lung tissue of healthy volun-
teers,29,42 there are limited data available to evaluate the ade-
quacy of these dosing regimens in infected patients.
Fluoroquinolones
Fluoroquinolones such as levofloxacin generally show
excellent penetration into intrapulmonary sites.14,30,31 Some
studies have shown parallel relationships between plasma and
ELF concentrations of levofloxacin after oral and IV
administration.30,31 Figure 1 is a PK model describing this
relationship and suggests that at steady state, plasma PK could
be used to guide dosing when the lung is the source of infec-
tion. Peak concentrations will be achieved in the ELF
TABLE 2. (continued)
Antibiotics
Dosage
Regimen
Population [No.
Patients (n)]
Sampling
Time (h)w
Plasma
Concentration
(mg/L)z
ELF
Concentration
(mg/L)z
ELF:Plasma
Ratioz
Probability PD
Target
Attainment in
ELF*
Vancomycin
(Lodise
et al33)
1000mg 12 h9
doses (IV)
Healthy subjects
(n = 10)
4 and 12 NA NA 0.7 ± 0.7z Low
(MIC> 1mg/L)
Teicoplanin
(Mimoz
et al21)
12mg/kg
12 h2 d, then
12mg/kg daily
Critically ill patient
with VAP (n = 13)
18-24 3.7 (2.0-5.4)y 4.9 (2.0-11.8)y 1.3 (0.5-3.3)y Low
Aminoglycosides
Tobramycin
(Boselli
et al17)
7-10mg/kg
daily2 doses
Critically ill patients
with VAP (n = 12)
0.5 22.4 ± 5.9 2.7 ± 0.7 0.1 ± 0.0 Low
Gentamicin
(Panidis
et al18)
240mg daily1
dose
Critically ill patients
with VAP (n = 24)
0.5
1
2
4
6
13.4 ± 0.9
8.8 ± 0.6
6.4 ± 0.5
4.7 ± 0.5
3.8 ± 0.6
NA
3.0 ± 0.4
4.2 ± 0.4
3.1 ± 0.4
2.7 ± 0.4
NA
0.3 ± 0.1
0.9 ± 0.1
1.1 ± 0.3
0.7 ± 0.2
Low
Oxazolidinones
Linezolid
(Boselli
et al16)
600mg 12 h2 d
(IV)
Critically ill patients
with VAP (n = 16)
1
12
17.7 ± 4.0
2.4 ± 1.2
14.4 ± 5.6
2.6 ± 1.7
1.1 ± 0.3
1.0 ± 0.3
Medium
(MIC< 4mg/L)
Linezolid
(Boselli
et al34)
600mg (LD),
then 1200mg/d
(CI)2 d
Critically ill patients
with VAP (n = 12)
48 7.1 (6.1-9.8)y 6.9 (5.8-8.6)y 1.0 (0.8-1.1)y Medium
(MIC< 4mg/L)
Others
Colistin
(Imberti
et al35)
2mU 8h (at least
2 d)
Critically ill patients
with VAP (n = 13)
1
8
2.2 ± 1.1
1.0 ± 0.7
0.0 0.0 Low
Colistin
(Markou
et al36)
225mg 8 h
(4-12 d)
Critically ill patients
(n = 2)
1.5-4.0 3.3 ± 0.48 15.3 ± 14.88 4.6 ± 4.08 NA
*Susceptibility breakpoint based on EUCAST 5 and targeted PD indices 7–9 of at least 50% fT>4xMIC for b-lactam, AUC0-24/MIC> 25 for macrolide, AUC0-24/
MIC > 125 for levofloxacin, AUC0-24/MICZ400 for glycopeptide, Cmax/MICZ10 for aminoglycoside, AUC0-24/MIC > 50 for linezolid, and AUC0-24/MICZ50 for
colistin, unless otherwise stated.
wSampling time after the last dose.
zValue expressed as mean ± SD unless specified otherwise.
yValue expressed as median (range).
8Calculated value based on reported data.
zValue based on AUC0-24 (mg h/L).
#Patients with no to mild renal impairment.
**Patients with moderate to advanced renal impairment.
CI indicates continuous infusion; ELF, epithelial lining fluid; H, hourly; IV, intravenous; LD, loading dose; MRSA, methicillin-resistant Staphylococcus aureus;
NA, data not available; VAP, ventilator-associated pneumonia.
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approximately an hour after administration.30,31 Standard
doses of levofloxacin rarely achieved the desired PK/PD tar-
gets in infected younger patients and those without renal
impairment.12 In critically ill patients, the administration of a
higher doses (eg, 1000mg/d) achieve the targeted PK/PD
index, AUC0-24/MIC> 125 for levofloxacin in ELF.
31 Ach-
ieving these PK/PD targets is important with 1 study finding
that when the PK/PD targets were achieved, >85% had
microbiological and clinical cure. Importantly, dose adjust-
ment should be considered necessary in renal dysfunction or in
the elderly, as these patients will have a reduced clearance of
levofloxacin.12,13 With the excellent penetration into the lung
tissue, use of fluoroquinolones in lung infections is usually
reliable as long as pathogen susceptibility remains acceptable.
Higher dosing regimens will be of course necessary when
aiming for a more aggressive PK/PD targets.
Glycopeptides
Vancomycin was shown to penetrate well (B70%) in
noninfected lung tissue33 as compared with critically ill
patients with pneumonia (< 20%).19,32 However, in healthy
volunteers, standard dosing (1 g IV 12 h) rarely achieved the
desired PK/PD target, AUC0-24/MIC ratio of Z400 in the ELF
(assuming an MIC 1mg/L).33 Thus with the poor lung pene-
tration in infected patients, standard dosing would rarely ach-
ieve sufficient drug exposures in the ELF. Maintaining a
constant plasma concentration (eg, 20mg/L) to enhance drug
concentrations in the lung compartment,19,32 supports the use
of therapeutic drug monitoring (TDM) to guide dosing with
vancomycin.43 The use of vancomycin to treat less susceptible
pathogens in lung infection could be considered unreliable due
to this low penetration and the need for higher doses to achieve
the PK/PD target in the lung compartments, although clinical
studies do not strongly reflect this at this time.44
Aminoglycosides
Similar to other hydrophilic antibiotics, aminoglycosides
(eg, tobramycin, gentamicin, amikacin) are not considered to
penetrate well into the pulmonary compartments. In critically
ill patients with VAP,17,18 standard dosing regimens failed to
achieve the target PK/PD index, Cmax/MIC> 10. As amino-
glycosides poorly penetrate the lung tissue, higher doses may
be required to treat severe lung infections. However, aiming
for aggressive dosing with aminoglycosides may be imprac-
tical due to the potential toxicity associated with high doses.
Oxazolidinones
Linezolid had shown excellent penetration (> 100%) into
the pulmonary compartments in critically ill patients with
VAP.16,34 The administration of standard doses (eg, 1200mg/
d) commonly achieved PK/PD targets for pathogens with a
susceptibility breakpoint of <4mg/L in the ELF.16 Fur-
thermore, CI has been shown to be advantageous for achieving
even higher PK/PD target attainment.34 The measurement of
unbound concentrations in the ELF for oxazolidinones may be
necessary to guide for optimal dosing.
Others
Limited data are available to provide robust dosing for
colistin during lung infections. Variable reports of colistin
penetration into the lung tissue have been published. Imberti
et al35 reported an undetectable colistin concentration in BAL
at steady state, after at least 2 days therapy of a lower dose
(174mg IV 8 h). However, in another study, the administration
of a 30% higher dose of colistin (225mg IV 8 h) in 2
mechanically ventilated trauma patients showed better ELF
penetration, with a high ELF:plasma ratio of 5.36 Despite the
conflicting results, both of these reports agree that a higher
dosing regimen is required to treat severe lung infections,
particularly in critically ill patients.35,36 The variation of pen-
etration above is likely to be related to the nature of the lung
injury, rather than other drug-related factors. It follows that
consideration of inhaled colistin is warranted in these clinical
scenarios.
ALTERNATIVE DOSING STRATEGIES:
NEBULIZATION
Nebulization has been used for many years to deliver
drugs into the lung compartments. In recent years, this method
has also been extended for antibiotic treatment of lung infec-
tions. Nebulization aims to enhance the amount of antibiotic at
the site of lung infection by delivering the drug at an ana-
tomically closer location, which can also lead to reduced
systemic exposure of drug. This mode of administration has
been applied for hydrophilic antibiotics that have traditionally
been considered to poorly penetrate the lung tissue. PK studies
reporting antibiotic concentrations in the lung compartments
using nebulization are becoming increasingly reported.45,46
Athanassa et al45 evaluated 20 critically ill patients with ven-
tilator-associated tracheobronchitis treated with nebulized
colistin. After the first nebulization, the median ELF concen-
trations were 6.7 and 2.0mg/L at 1 and 8 hours, respectively.
At these times, the median concentration in serum were 1.2
and 0.31mg/L, respectively, indicating higher colistin
FIGURE 1. A pharmacokinetic description of drug distribution
between blood and alveolar compartments. After drug admin-
istration (IV/PO), drug distributes from the blood compartment
to the peripheral compartment (alveolar) (distribution phase). At
steady state, the concentration of drug in blood (C1) and alveolar
(C2) are equivalent. Drug is removed from the body through the
elimination rate constant (Ke). Clearance (CL) = KeVd, where Vd
is the apparent volume of distribution which is the sum of V1 +V2
(V1 is volume of distribution in blood and V2 is volume of dis-
tribution in alveolar compartments). AM indicates alveolar mac-
rophage; ELF, epithelial lining fluid; IV, intravenous; Ko, rate
constant after IV administration; Ka, absorption rate constant after
oral administration; K12, transfer rate constant from blood to
alveolar compartments; K21, transfer rate constant from alveolar
compartments to blood; PO, by mouth.
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concentrations can be achieved in the ELF with nebulization,45
which suggests improved target site concentrations with neb-
ulization. Luyt et al46 similarly showed favorable amikacin
concentrations in ELF in a study of 28 mechanically ventilated
patients with gram-negative VAP. In this study, patients
received nebulized amikacin through an advanced nebulizer
system as an adjunct to IV therapy. The median peak amikacin
concentration in the ELF (976mg/L) was far higher than that
observed in serum (0.85mg/L).46
With the advancement of this antibiotic delivery system,
nebulization may prove to be an effective alternative method
of administration to improve antibiotic concentrations in the
lung tissue. However, issues relating to appropriate dose
selection in the context of pathogen susceptibility need to be
considered.45 Further, TDM to prevent any local or systemic
unwanted effects46 as well as use of a specially formulated
antibiotic solutions for inhalation and delivery devices should
be considered.46
RECOMMENDED DOSING APPROACH DURING
LUNG INFECTION
The published data on the ELF:plasma ratios provide only a
moderate level of understanding of antibiotic disposition in the
lung. Evaluation of PK/PD target attainment in the ELF with
current dosing regimens is required to define the optimal anti-
biotic dosing strategies for treatment of lung infections (Fig. 2).
Lipophilic antibiotics generally penetrate well into the
lung tissue, and thus standard dosing will achieve the PK/PD
targets for susceptible pathogens. Aggressive dosing may be
necessary for treatment of less susceptible pathogens. Dosing
for hydrophilic antibiotics is more challenging, particularly in
critically ill patients. Standard dosing regimens rarely achieve
the PK/PD targets in the lung tissue. The problem is likely to
be heightened in patients with altered antibiotic clearance (CL)
(eg, augmented renal clearance, renal replacement ther-
apy)47,48 and/or an increased volume of distribution (eg, crit-
ically ill patients, burns),49,50 and therefore higher doses may
be necessary in these populations. Use of nebulization to
enhance drug delivery into the lung compartments is likely to
be advantageous as well.
The bacterial kill characteristics of the different classes of
antibiotics should be used to guide dosing. Aiming for a high
Cmax:MIC ratio using larger doses is especially important for
antibiotic classes like the aminoglycosides. More frequent
administration to maximize the percentage of time in which the
free antibiotic concentration is above the MIC (%f T>MIC)
should be considered for time-dependent antibiotics like the
b-lactams. Alternatively, use of extended infusion or CI should
be considered as other approaches to increase f T>MIC.
Administration of intermittent doses can enable achievement
of target AUC0-24/MIC ratios for antibiotic classes such as the
fluoroquinolones.
CONCLUSIONS
Antibiotic dosing for lung infections is challenging and
understanding the relationship between the antibiotic and the
pathophysiology changes in the lung during an infection is
required. The alveolar compartments (ELF, AM) best represent
the site of infection in the lung, and as such dose adjustment
based on the antibiotic penetration into the ELF or AM may
lead to the development of better antibiotic dosing regimens to
treat lung infections. TDM should be utilized whenever pos-
sible as a mechanism to optimize dosing.
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